Renal denervation: recent developments in clinical and preclinical research.
Journal
Current opinion in nephrology and hypertension
ISSN: 1473-6543
Titre abrégé: Curr Opin Nephrol Hypertens
Pays: England
ID NLM: 9303753
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
3
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
Renal denervation represents a new dimension to hypertension treatment, with multiple device manufacturers seeking premarket FDA approval currently. Interest in the efficacy and safety of the treatment has spurred compelling mechanistic studies into the function of renal nerves and downstream impacts of denervation. A trial of the ultrasound Paradise Catheter system (RADIANCE II) found a 6.3 mmHg reduction in SBP relative to sham controls. A trial of the Symplicity Spyral system (SPYRAL HTN-ON MED) found an insignificant reduction in SBP relative to sham controls. Individuals were taking antihypertensive medications during the study, and investigators note the sham group experienced a larger medication burden than the denervated group. Recent preclinical studies have evaluated potential risks of renal denervation, how sympathetic activity broadly is affected, as well as identifying possible biomarkers to identify individuals where denervation would be more successful. Studies of renal denervation continue to find a robust antihypertensive effect, especially in studies wherein medications are withdrawn. Further investigation into mechanisms and indicators for usage of the technique will be important in identifying the patient population most likely to benefit from usage of renal denervation.
Identifiants
pubmed: 37530084
doi: 10.1097/MNH.0000000000000908
pii: 00041552-202309000-00003
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
404-411Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224–2260.
Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension 2016; 68:297–306.
Mahfoud F, Renkin J, Sievert H, et al. Alcohol-mediated renal denervation using the Peregrine System Infusion Catheter for treatment of hypertension. JACC Cardiovasc Interv 2020; 13:471–484.
Hering D, Nikoleishvili D, Imedadze A, et al. Transurethral renal pelvic denervation: a feasibility trial in patients with uncontrolled hypertension. Hypertension 2022; 79:2787–2795.
Mauri L, Kario K, Basile J, et al. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: the RADIANCE-HTN and REQUIRE clinical study designs. Am Heart J 2018; 195:115–129.
Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391:2335–2345.
Azizi M, Saxena M, Wang Y, et al. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II Randomized Clinical Trial. JAMA 2023; 329:651–661.
Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 2021; 397:2476–2486.
Azizi M, Mahfoud F, Weber MA, et al. Effects of renal denervation vs sham in resistant hypertension after medication escalation: prespecified analysis at 6 months of the RADIANCE-HTN TRIO randomized clinical trial. JAMA Cardiol 2022; 7:1244–1252.
Kario K, Yokoi Y, Okamura K, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res 2022; 45:221–231.
Kandzari DE, Kario K, Mahfoud F, et al. The SPYRAL HTN Global Clinical Trial Program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J 2016; 171:82–91.
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 2020; 395:1444–1451.
David E, Kandzari M, Anthony FACC, et al. Investigation of catheter-based renal denervation in patients with uncontrolled hypertension in the presence of antihypertensive medications: SPYRAL HTN-ON MED in AHA. Presented by Dr. David E. Kandzari at the American Heart Association Scientific Sessions, Chicago, IL, November 7, 2022.
Ahmad Y, Francis DP, Bhatt DL, et al. Renal denervation for hypertension: a systematic review and meta-analysis of randomized, blinded, placebo-controlled trials. JACC Cardiovasc Interv 2021; 14:2614–2624.
Ogoyama Y, Tada K, Abe M, et al. Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials. Hypertens Res 2022; 45:210–220.
Banek CT, Gauthier MM, Baumann DC, et al. Targeted afferent renal denervation reduces arterial pressure but not renal inflammation in established DOCA-salt hypertension in the rat. Am J Physiol Regul Integr Comp Physiol 2018; 314:R883–R891.
Ong J, Kinsman BJ, et al. Renal sensory nerves increase sympathetic nerve activity and blood pressure in 2-kidney 1-clip hypertensive mice. J Neurophysiol 2019; 122:358–367.
Milanez MIO, Veiga AC, Martins BS, et al. Renal sensory activity regulates the γ-aminobutyric acidergic inputs to the paraventricular nucleus of the hypothalamus in Goldblatt hypertension. Front Physiol 2020; 11:601237–1601237.
DeLalio LJ, Stocker SD. Sympathoexcitatory responses to renal chemosensitive stimuli are exaggerated at nighttime in rats. Am J Physiol Heart Circ Physiol 2022; 323:H437–h448.
Cheng X, Zhang Y, Chen R, et al. Anatomical evidence for parasympathetic innervation of the renal vasculature and pelvis. J Am Soc Nephrol 2022; 33:2194–2210.
Townsend RR, Walton A, Hettrick DA, et al. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention 2020; 16:89–96.
Singh RR, McArdle Z, Booth LC, et al. Renal denervation in combination with angiotensin receptor blockade prolongs blood pressure trough during hemorrhage. Hypertension 2022; 79:261–270.
Sata Y, Burke SL, Gueguen C, et al. Contribution of the renal nerves to hypertension in a rabbit model of chronic kidney disease. Hypertension 2020; 76:1470–1479.
Sata Y, Burke SL, Eikelis N, et al. Renal deafferentation prevents progression of hypertension and changes to sympathetic reflexes in a rabbit model of chronic kidney disease. Hypertension 2021; 78:1310–1321.
Gauthier MM, Dennis MR, Morales MN, et al. Contributions of afferent and sympathetic renal nerves to cystogenesis and arterial pressure regulation in a preclinical model of autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 2022; 322:F680–F691.
Zhu B, Liu Y, Qi D, et al. Renal interstitial fibrosis is reduced in high-fat diet-induced obese pigs following renal denervation from the intima and adventitia of the renal artery. Kidney Blood Press Res 2021; 47:135–146.
Li Q, Deng Y, Liu L, et al. Sympathetic denervation ameliorates renal fibrosis via inhibition of cellular senescence. Front Immunol 2022; 12:823935.
Sata Y, Schlaich MP. The potential role of catheter-based renal sympathetic denervation in chronic and end-stage kidney disease. J Cardiovasc Pharmacol Ther 2016; 21:344–352.
Hoogerwaard AF, de Jong MR, Adiyaman A, et al. Renal sympathetic denervation induces changes in heart rate variability and is associated with a lower sympathetic tone. Clin Res Cardiol 2019; 108:22–30.
Hawson J, Harmer JA, Cowan M, et al. Renal denervation for the management of refractory ventricular arrhythmias. JACC Clin Electrophysiol 2021; 7:100–108.
Liu S-H, Lo L, Chou Y, et al. Renal denervation prevents myocardial structural remodeling and arrhythmogenicity in a chronic kidney disease rabbit model. Heart rhythm 2021; 18:1596–1604.
Wang K, Qi Y, Gu R, et al. Renal denervation attenuates adverse remodeling and intramyocardial inflammation in acute myocardial infarction with ischemia-reperfusion injury. Front Cardiovasc Med 2022; 9:832014.
Araujo M, Solis G, Welch WJ, et al. Renal nerve deafferentation attenuates the fall in GFR during intravenous infusion of furosemide in anesthetized rats. Kidney Blood Press Res 2020; 45:70–83.
Katsurada K, Nandi SS, Sharma NM, et al. Does glucagon-like peptide-1 induce diuresis and natriuresis by modulating afferent renal nerve activity? Am J Physiol Renal Physiol 2019; 317:F1010–f1021.
Katsurada K, Nandi SS, Sharma NM, et al. Enhanced expression and function of renal SGLT2 (Sodium-Glucose Cotransporter 2) in heart failure: role of renal nerves. Circ Heart Fail 2021; 14:e008365–e18365.
Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 2015; 36:219–227.
Fudim M, Sobotka AA, Yin Y, et al. Selective vs. global renal denervation: a case for less is more. Curr Hypertens Rep 2018; 20:37.
Hoogerwaard AF, Adiyaman A, de Jong MR, et al. Renal nerve stimulation: complete versus incomplete renal sympathetic denervation. Blood Press 2021; 30:376–385.
Pellegrino PR, Zucker IH, Chatzizisis YS, et al. Quantification of renal sympathetic vasomotion as a novel end point for renal denervation. Hypertension 2020; 76:1247–1255.
Kantauskaite M, Vonend O, Yakoub M, et al. The effect of renal denervation on T cells in patients with resistant hypertension. Int J Mol Sci 2023; 24:2493.
Banek CT, Gauthier MM, Van Helden DA, et al. Renal inflammation in DOCA-Salt hypertension. Hypertension 2019; 73:1079–1086.